Edition:
India

MiMedx Group Inc (MDXG.OQ)

MDXG.OQ on NASDAQ Stock Exchange Capital Market

7.43USD
1:30am IST
Change (% chg)

$0.03 (+0.41%)
Prev Close
$7.40
Open
$7.57
Day's High
$7.65
Day's Low
$7.36
Volume
677,764
Avg. Vol
867,960
52-wk High
$18.24
52-wk Low
$6.05

Latest Key Developments (Source: Significant Developments)

Mimedx Reports Positive Results From Phase 2B Clinical Trial Of Amniofix Injectable
Monday, 26 Mar 2018 

March 26 (Reuters) - Mimedx Group Inc ::MIMEDX REPORTS POSITIVE PAIN AND FOOT FUNCTION RESULTS FROM PHASE 2B CLINICAL TRIAL OF AMNIOFIX® INJECTABLE IN THE TREATMENT OF PLANTAR FASCIITIS.MIMEDX GROUP INC - AMNIOFIX INJECTABLE ACHIEVES PRIMARY AND SECONDARY EFFICACY ENDPOINTS.MIMEDX GROUP INC - ‍STATISTICALLY SIGNIFICANT DIFFERENCE IN PAIN AND FUNCTION COMPARED TO PLACEBO​.  Full Article

Mimedx Comments On Magistrate Recommendation In Co's Lawsuit Against Short Sellers
Thursday, 18 Jan 2018 

Jan 18 (Reuters) - Mimedx Group Inc ::MIMEDX COMMENTS ON MAGISTRATE RECOMMENDATION IN THE COMPANY'S LAWSUIT AGAINST SHORT SELLERS.MIMEDX GROUP INC - "‍BELIEVES THAT MAGISTRATE'S RECOMMENDATIONS ARE IN ERROR, AND THEREFORE MIMEDX WILL BE FILING OBJECTIONS WITH DISTRICT COURT JUDGE​".  Full Article

Mimedx Settles Patent Infringement Lawsuit
Friday, 12 Jan 2018 

Jan 11 (Reuters) - Mimedx Group Inc ::MIMEDX - SUCCESSFULLY SETTLED CO'S PATENT INFRINGEMENT LAWSUIT AGAINST MUSCULOSKELETAL TRANSPLANT FOUNDATION, MEDLINE INDUSTRIES, LIVENTA BIOSCIENCE.MIMEDX - ‍HAS OBTAINED CONSENT DECREE AND FINAL JUDGMENT ON VALIDITY OF U.S. PATENT NO. 8,709,494​, AND WILL RECEIVE UNDISCLOSED MONETARY SUM.  Full Article

MiMedx Agrees To Lawsuit Settlement With Former Employee
Tuesday, 19 Dec 2017 

Dec 19 (Reuters) - MiMedx Group Inc ::MIMEDX AGREES TO LAWSUIT SETTLEMENT WITH FORMER EMPLOYEE.MIMEDX GROUP INC - COMPANY HAS AGREED TO A CONFIDENTIAL LAWSUIT SETTLEMENT FROM ONE FORMER EMPLOYEE.MIMEDX GROUP INC - WILLIAM​ ‍MILLS HAS AGREED NOT TO SELL ANY PRODUCTS OF HIS CURRENT EMPLOYER TO ANY MIMEDX CUSTOMER SERVICED BY MILLS FOR NINE MONTHS.  Full Article

MiMedx Forecasts 2018 Revenue To Be In Range Of $383 Mln To $387 Mln
Wednesday, 13 Dec 2017 

Dec 13 (Reuters) - MiMedx Group Inc ::MIMEDX FORECASTS 2018 REVENUE TO BE IN THE RANGE OF $383 MILLION TO $387 MILLION.SEES FY 2018 ADJUSTED EARNINGS PER SHARE $0.45 TO $0.50 EXCLUDING ITEMS.SEES FY 2018 GAAP EARNINGS PER SHARE $0.30 TO $0.35.SEES FY 2018 REVENUE $383 MILLION TO $387 MILLION.FY2018 EARNINGS PER SHARE VIEW $0.43 -- THOMSON REUTERS I/B/E/S.  Full Article

MiMedx Says It Expects To Exceed Top End Of Q4 Revenue Guidance Of $88 Mln
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Mimedx Group Inc ::MIMEDX ANNOUNCES EXPECTATION TO EXCEED TOP END OF FOURTH QUARTER REVENUE GUIDANCE OF $88 MILLION.SEES Q4 2017 REVENUE MORE THAN $88 MILLION.Q4 REVENUE VIEW $88.0 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Mimedx provides update on its reimbursement coverage
Tuesday, 21 Nov 2017 

Nov 21 (Reuters) - Mimedx Group Inc :Mimedx provides update on its reimbursement coverage.Mimedx Group Inc - ‍provided a reimbursement update in light of FDA final and draft guidance documents related to human tissue​.Mimedx Group Inc - "‍with issuance of final hct/p guidance document by FDA, we believe payer coverage for epifix will further improve"​.  Full Article

MiMedx Group sees FY 2017 revenue $320.6 million to $321.6 million
Friday, 17 Nov 2017 

Nov 17 (Reuters) - MiMedx Group Inc :Sees q4 2017 revenue $87 million to $88 million.Sees FY 2017 revenue $320.6 million to $321.6 million.MiMedx Group Inc - ‍reiterates Q4 and full year 2017 guidance​.FY2017 earnings per share view $0.33, revenue view $321.5 million -- Thomson Reuters I/B/E/S.  Full Article

MiMedx group says agreed to lawsuit settlement with Halo Wound Solutions
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - MiMedx Group Inc ::Agreed to confidential settlement of lawsuit co filed against BioResolutions LLC d/b/a Halo Wound Solutions and one of Halo executives​.In addition to an undisclosed monetary settlement, other settlement terms were reached related to lawsuit with Halo Wound Solutions​.  Full Article

MiMedx announces Q3 2017 results
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Mimedx Group Inc :MiMedx announces record results for third quarter of 2017 and raises full year revenue guidance.Q3 adjusted earnings per share $0.08.Q3 gaap earnings per share $0.15.Q3 revenue $84.6 million versus i/b/e/s view $80.1 million.Q3 earnings per share view $0.08 -- Thomson Reuters I/B/E/S.Sees Q4 2017 revenue $87 million to $88 million.Sees FY 2017 revenue $320.6 million to $321.6 million.Says an additional increase of $10 million to share repurchase program was authorized by MiMedx board​.Says GAAP EPS(FD) for 2017 projected to be in range of $0.31 to $0.32​.Says ‍adjusted EPS(FD) for 2017 projected to be in range of $0.31 to $0.32​.Q4 earnings per share view $0.09, revenue view $83.1 million -- Thomson Reuters I/B/E/S.FY 2017 earnings per share view $0.31, revenue view $312.2 million -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-MiMedx Enrolls First Patient In Its Phase 2B Clinical Trial Of Amniofix® Injectable For Treatment Of Osteoarthritis Of The Knee

* MIMEDX ENROLLS FIRST PATIENT IN ITS PHASE 2B CLINICAL TRIAL OF RMAT DESIGNATED AMNIOFIX® INJECTABLE FOR THE TREATMENT OF OSTEOARTHRITIS OF THE KNEE Source text for Eikon: Further company coverage: